Tech Company Financing Transactions
Orexigen Therapeutics Funding Round
Orexigen Therapeutics secured a $30 million Series C investment round on 11/22/2006. Backers included Domain Associates, EPIC Ventures and Kleiner Perkins Caufield & Byers.
Transaction Overview
Company Name
Announced On
11/22/2006
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the Series C financing will be used to advance OREXIGEN's clinical programs for its two lead drug candidates for the treatment of obesity and for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3344 N. Torrey Pines Ct. 200
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
OREXIGEN is studying a novel, and potentially more effective way, to achieve and sustain weight loss through a combined, two-drug approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Narachi
Chief Financial Officer
Monica Forbes
Chief Operating Officer
Thomas Cannell
VP - Bus. Development
Peter Flynn
VP - General Counsel
Thomas Lynch
Browse more venture capital transactions:
Prev: 11/21/2006: Natural Convergence venture capital transaction
Next: 11/22/2006: Equity Administration Solutions venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs